Adakveo - direct healthcare professional communication (DHPC)

Crizanlizumab
DHPCHuman

Slovenian is available via eTranslation, the European Commission's machine translation service.

Translate to Slovenian | Important information about machine translation

O modulu

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Dokumenti

Direct healthcare professional communication (DHPC) : ADAKVEO (crizanlizumab): revocation of EU marketing authorisation due to lack of therapeutic efficacy

English (EN) (116.64 KB - PDF)

Prva objava:
Prikaži

Key facts

Medicine name
Adakveo
Active substance
Crizanlizumab
Therapeutic area (MeSH)
Anemia, Sickle Cell
Procedure number
EMEA/H/A-20/1525/C/4874/0013
Regulatory outcome
Revocation
DHPC type
  • Lack of effect
  • Referral - Article 20 procedure
Human ATC codes
B06AX01
Dissemination date

Share this page